CVRx, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CVRx, Inc. (CVRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $7.83 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- CVRx, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $8.16, a 38.28% decline year-over-year.
- CVRx, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $13.22, a 11.51% decline year-over-year.
- CVRx, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $14.94, a 7.33% increase year-over-year.
- CVRx, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $13.92, a 57.29% increase year-over-year.
- CVRx, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $11.56, a 9.48% decline from fiscal 2024.
- CVRx, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $12.77, a 10.07% decline from fiscal 2023.
- CVRx, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $14.20, a 74.45% increase from fiscal 2022.
- CVRx, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.14, a 38.84% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.83 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $8.16 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $11.56 10-K · filed 2026-02-13 | |||
| 2025-09-30 | $11.62 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $12.03 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $13.22 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $12.77 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $12.75 10-Q · filed 2024-11-01 | |||
| 2024-06-30 | $13.36 10-Q · filed 2024-08-02 | |||
| 2024-03-31 | $14.94 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | $14.20 10-K · filed 2025-02-18 | |||
| 2023-09-30 | $14.06 10-Q · filed 2023-10-31 | |||
| 2023-06-30 | $13.73 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $13.92 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $8.14 10-K · filed 2023-02-10 | |||
| 2022-09-30 | $7.87 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $7.56 10-Q · filed 2022-08-01 | |||
| 2022-03-31 | $8.85 10-Q · filed 2022-05-02 | |||
| 2021-12-31 | $13.31 10-K · filed 2023-02-10 | |||
| 2021-09-30 | $13.00 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $12.80 10-Q · filed 2021-08-09 | |||
| 2020-12-31 | $4.35 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |